GLP-1 medications like semaglutide and tirzepatide have transformed obesity treatment. They reduce appetite, slow gastric emptying, and promote significant weight loss.
What Experts Say About GLP-1s and Eating Disorders
A new consensus article in World Psychiatry outlines the risks and benefits of GLP-1s for people with eating disorders. It was developed through a Delphi process with 45 experts and individuals who have lived experience of eating disorders. This ensures both clinical insight and patient perspectives are included.
Experts agree GLP-1s may help some people with binge eating disorder. But evidence remains limited. Most studies are small, uncontrolled, or based on past data. One well-designed trial found no reduction in binge episodes with liraglutide versus placebo. The drug caused weight loss but did not improve binge behavior. This suggests appetite suppression alone does not fix the core psychological issues of BED.
Key Risks: Restriction and Relapse
Several clinical cases show people with a history of anorexia nervosa developing extreme dietary restriction while on GLP-1s. Dr. Riccardo Dalle Grave, a clinical psychiatrist, has seen similar cases in practice. These patients, once struggling with rigid eating, began adopting even stricter behaviors under reduced appetite and increased fullness signals.
Gastrointestinal side effects like nausea and vomiting can worsen symptoms. These effects may trigger purging or reinforce unhealthy coping. The physiological effects—such as delayed digestion and fullness—can be misinterpreted as control over food. This may give a false sense of mastery over eating behaviors.
Screening and Patient Assessment
Experts recommend screening for any current or past eating disorders before starting GLP-1 treatment. This includes diagnosing anorexia nervosa, bulimia nervosa, and binge eating disorder.
Screening should not rely only on self-report or body weight. It must use validated tools and interviews to assess body image, dietary restraint, and emotional regulation around food. This helps catch subtle or atypical signs missed by weight-based evaluations.
When to Avoid or Use with Caution
These conditions are not absolute contraindications. But they represent high-risk situations where GLP-1s may worsen symptoms or trigger relapse.
People with a history of these disorders need caution. Past symptoms, even if resolved, may still affect how they respond to appetite-suppressing drugs. Decisions must be case-by-case, with ongoing monitoring and multidisciplinary support.
Binge Eating Disorder: A Complex Case
BED presents a nuanced situation. GLP-1s may help reduce food intake and improve weight trends in some. But they may worsen core issues like over-evaluation of shape and weight, marked dietary restriction, and fear of weight gain. These factors can harm recovery and must be assessed before and during treatment.
What Monitoring Should Include
Continuous monitoring is essential during GLP-1 therapy. Experts recommend tracking weight, binge frequency, food intake, hunger and satiety, physical health, and quality of life. Assessments should happen monthly or every two months to catch early signs of decline.
Patients often describe ‘food noise’—persistent, intrusive thoughts about food. GLP-1s seem to reduce these thoughts, offering relief. But less food-related thinking does not mean better recovery. A person may still have rigid eating rules, intense fear of weight gain, or obsessive body image concerns. These remain central to eating disorder diagnosis and treatment.
What’s Next in Research
Future studies must go beyond weight and binge frequency. They should assess dietary restriction, body image, emotional regulation, and psychological eating behaviors. Long-term, diverse studies are needed to understand how GLP-1s affect the full range of eating disorder symptoms.
Until such research is available, GLP-1s should not be used alone for eating disorders. They require careful evaluation, personalized decisions, and integration with mental health care. This guidance supports safer, more informed prescribing.
For patients, GLP-1s are not a cure. They are a tool. They must be used carefully and within a broader therapeutic framework. Mental health care should not be replaced or substituted, especially for complex psychological conditions.
Read the full expert consensus article.
Sources & further reading
Featured image: original publisher image. Via original publisher. Image source
